Melatonin as a candidate compound for neuroprotection in amyotrophic lateral sclerosis (ALS): high tolerability of daily oral melatonin administration in ALS patients.
Jacob
Sonja
S
Poeggeler
Burkhard
B
Weishaupt
Jochen H
JH
Sirén
Anna-Leena
AL
Hardeland
Rüdiger
R
Bähr
Mathias
M
Ehrenreich
Hannelore
H
D000284:Administration, Oral; D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy* / Q000503:physiopathology; D000975:Antioxidants / Q000008:administration & dosage; D004361:Drug Tolerance; D006801:Humans; D008550:Melatonin / Q000008:administration & dosage*; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D018384:Oxidative Stress / Q000187:drug effects; D010865:Pilot Projects
D000975:Antioxidants; D018696:Neuroprotective Agents; D008550:Melatonin